Bristol-Myers Squibb Announces European Commission Approval Of Empliciti Plus Pomalidomide And Low-Dose Dexamethasone (EPd) For Treatment Of Patients With Relapsed And Refractory Multiple Myeloma
Benzinga Newsdesk